Showing results (1-10 of 14) with videos related to
Sort By:
Pageof 2
The Journal of Physician Assistant Education : the Official Journal of the Physician Assistant Education Association|July 1, 2026
Impact of CASPer Cut Score on Diversity in Physician Assistant Program AdmissionsSara Lolar, Bindiya Nandwana, Mary Jo PilatCurrent Oncology Reports|January 31, 2004
Vascular targeting agentsMary Jo Pilat, Julie McCormick, Patricia Mucci LoRussoJournal of Allied Health|September 3, 2020
Impact of Type of Healthcare Experience Before Physician Assistant School Admission on PANCE ScoreSara Lolar, Mary Jo Pilat, Robert D WelchClinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2008
Effect of food on the pharmacokinetic behavior of the potent oral taxane BMS-275183Linda E Bröker, Manual Valdivieso, Mary Jo Pilat, et al.Cancer Chemotherapy and Pharmacology|April 5, 2011
Lack of food effect on single-dose pharmacokinetics of brivanib, and safety and efficacy following multiple doses in subjects with advanced or metastatic solid tumorsPatricia LoRusso, Geoffrey I Shapiro, Herbert Hurwitz, et al.Investigational New Drugs|June 25, 2008
Effect of coadministration of ketoconazole, a strong CYP3A4 inhibitor, on pharmacokinetics and tolerability of motesanib diphosphate (AMG 706) in patients with advanced solid tumorsPatricia Lorusso, Elisabeth I Heath, Jesse McGreivy, et al.Cancer Research Communications|June 28, 2023
NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid TumorsMichael Cecchini, Zenta Walther, Wei Wei, et al.Cancer Research Communications|March 27, 2023
Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent <i>IDH1-</i> and <i>IDH2</i>-mutant GliomaKristina Fanucci, Mary Jo Pilat, Derek Shyr, et al.Oncotarget|April 19, 2017
A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinomaPriscila H Goncalves, Lance K Heilbrun, Michael T Barrett, et al.Investigational New Drugs|April 26, 2019
Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumorsGeoffrey I Shapiro, Patricia LoRusso, Eunice Kwak, et al.Pageof 2